Form 8-K

8-K — APTARGROUP, INC.

Accession: 0000896622-26-000090

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0000896622

SIC: 3089 (PLASTICS PRODUCTS, NEC)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — atr-20260430.htm (Primary)

EX-99.1 (atr-20260331x8kexx991.htm)

GRAPHIC (image.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: atr-20260430.htm · Sequence: 1

atr-20260430

0000896622FALSE00008966222026-04-302026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

April 30, 2026

Date of Report (Date of earliest event reported)

AptarGroup, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-11846 36-3853103

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

265 Exchange Drive, Suite 301, Crystal Lake, Illinois 60014

(Address of principal executive offices)

Registrant’s telephone number, including area code: 815-477-0424.

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $.01 par value ATR New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On April 30, 2026, AptarGroup, Inc. announced certain information related to its results of operations for the quarter ended March 31, 2026. The press release regarding this announcement is furnished as Exhibit 99.1 hereto.

The information in Item 2.02 of this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1

Press release issued by AptarGroup, Inc. dated April 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AptarGroup, Inc.

Date: April 30, 2026

By: /s/ Vanessa Kanu

Vanessa Kanu

Executive Vice President and

Chief Financial Officer

EX-99.1

Filename: atr-20260331x8kexx991.htm · Sequence: 2

Document

Exhibit 99.1

Aptar Reports First Quarter 2026 Results

Crystal Lake, Illinois, April 30, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following first quarter results for the period ended March 31, 2026, as compared to the corresponding period of the last fiscal year.

First Quarter 2026 Highlights

(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)

•Reported sales increased 11% and core sales were flat

•Reported net income decreased 8% to $73 million and reported earnings per share decreased 4% to $1.12

•Adjusted earnings per share were $1.19, a decrease of 8%, compared to the prior year at constant currency

•Adjusted EBITDA margin was 19.2% compared to 20.7% in the prior year

•Returned $131 million to shareholders through share repurchases and dividends

•Gael Touya named Aptar’s next CEO effective September 1, 2026

“Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP‑1 therapies, biologics, systemic nasal drug delivery, nasal decongestants, ophthalmic dispensing, and active material solutions. As anticipated, first quarter results were impacted by emergency medicine destocking, with comparisons further challenged by the exceptionally strong prior-year quarter for the prescription division. The injectables division delivered another quarter of strong, double-digit growth. Consumer dispensing also contributed positively, with volume growth across Beauty and Closures, supported by robust demand in prestige fragrance and beverage applications,” said Stephan B. Tanda, Aptar President and CEO.

First Quarter Results

For the quarter ended March 31, 2026, reported sales increased 11% to $982.9 million compared to $887.3 million in the prior year period. Core sales were flat compared to the prior year period.

First Quarter Segment Sales Analysis

(Change Over Prior Year)

Pharma Beauty Closures Total AptarGroup

Reported Sales Growth 7% 19% 5% 11%

Currency Effects (1)

(7)% (9)% (5)% (8)%

Acquisitions (1)% (7)% 0% (3)%

Core Sales Growth (1)% 3% 0% 0%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

Pharma’s reported sales increased 7% when compared to the prior year period, with a currency contribution of 7%. Excluding acquisitions, core sales declined 1% in the quarter when compared to the prior year period. In the prescription division, sales for dispensing systems declined 10% primarily due to reduced sales in the emergency medicine category, as anticipated, while the pipeline for systemic nasal drug delivery continued to build. Consumer healthcare sales increased 4% on strong nasal decongestant and eye care solutions. Sales in the injectables division increased 20%, mainly driven by growth in demand for elastomeric components used for GLP-1, biologics and antithrombotics. Active material science solutions declined 1% due primarily to lower sales for diabetes test strips and probiotics. Adjusted EBITDA margin was 33.3%, a decrease of 150 basis points, reflecting a less favorable product mix, while royalties continued to positively impact margins.

Beauty’s reported sales increased 19% when compared to the prior year period, driven by a 9% benefit from currency changes and a 7% contribution from acquisitions, with core sales growth of 3%. There was increased demand for fragrance dispensing, as well as hair care and body care applications. Adjusted EBITDA margin was 11.1%, a decline of 100 basis points, due to less favorable product mix, primarily in North America and isolated operational disruptions at a supplier as reported last quarter.

Closures’ reported sales rose 5% from the prior year quarter and core sales were flat, with a 5% currency benefit. While product volumes were up, core sales results were negatively impacted by the pass through of lower resin pricing. Adjusted EBITDA margin was 13.1%, a decline of 270 basis points, primarily due to the previously reported maintenance issues, temporary plant closures as a result of extreme weather in North America and certain investment write offs.

Reported first quarter earnings per share were $1.12 compared to $1.17 reported a year ago. Adjusted earnings per share were $1.19, compared to the prior year period’s adjusted earnings per share of $1.30, including comparable exchange rates. The first quarter reported effective tax rate was 22.4% and the adjusted effective tax rate was 22.6%, compared to the prior year period’s reported and adjusted effective tax rates of 25.8%.

Outlook

Regarding Aptar’s outlook, Tanda stated, “Looking ahead to Q2, excluding destocking in emergency medicine within Pharma, we anticipate a solid quarter with growth across each segment. Outside of the emergency medicine end market, our prescription division is expected to return to healthy growth, and we anticipate growth across a number of pharma end markets mainly due to strength in our injectables and consumer healthcare divisions. We also anticipate a strong quarter for Closures and continued growth in Beauty, particularly in fragrance. Heading into the quarter, we remain mindful of potential supply‑chain uncertainties as we continue to operate in a dynamic environment.”

Aptar currently expects adjusted earnings per share for the second quarter of 2026 to be in the range of $1.32 to $1.40. This guidance assumes an effective tax rate range of 22.5% to 24.5%. The earnings per share guidance range is assuming a 1.18 Euro to USD exchange rate.

Cash Dividends and Share Repurchases

As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.48 per share. The payment date is May 27, 2026, to stockholders of record as of May 6, 2026. During the first quarter, Aptar repurchased 707 thousand shares for $100 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

Open Conference Call

There will be a conference call held on Friday, May 1, 2026 at 8:00 a.m. Central Time to discuss the company’s first quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in drug delivery and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 14,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. For the quarter ended March 31, 2026, “Other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring, acquisition costs and other special items.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; competition, including technological advances; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investor Relations Contact:

Mary Skafidas

mary.skafidas@aptar.com

815-479-5530

Media Contact:

Katie Reardon

katie.reardon@aptar.com

815-479-5671

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(In Thousands, Except Per Share Data)

Consolidated Statements of Income

Three Months Ended

March 31,

2026

2025

Net Sales $ 982,868 $ 887,305

Cost of Sales (exclusive of depreciation and amortization shown below) 630,959 550,891

Selling, Research & Development and Administrative 167,602 155,277

Depreciation and Amortization 75,725 65,647

Restructuring Initiatives 1,086 2,042

Operating Income 107,496 113,448

Other Income (Expense):

Interest Expense (16,942) (11,351)

Interest Income 3,642 2,814

Net Investment Loss (1,086) (1,096)

Equity in Results of Affiliates 714 2,086

Miscellaneous (Expense) Income, net (53) 114

Income before Income Taxes 93,771 106,015

Provision for Income Taxes 21,004 27,352

Net Income $ 72,767 $ 78,663

Net (Income) Loss Attributable to Noncontrolling Interests (4) 135

Net Income Attributable to Redeemable Noncontrolling Interests (89) —

Net Income Attributable to AptarGroup, Inc. $ 72,674 $ 78,798

Net Income Attributable to AptarGroup, Inc. per Common Share:

Basic $ 1.13 $ 1.19

Diluted $ 1.12 $ 1.17

Average Numbers of Shares Outstanding:

Basic 64,050 66,271

Diluted 64,834 67,491

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Balance Sheets

March 31, 2026 December 31, 2025

ASSETS

Cash and Equivalents $ 222,529 $ 402,424

Short-term Investments 6,948 7,109

Accounts and Notes Receivable, Net 833,268 803,830

Inventories 551,482 537,845

Prepaid and Other 154,045 142,354

Total Current Assets 1,768,272 1,893,562

Property, Plant and Equipment, Net 1,660,929 1,676,479

Goodwill 1,072,560 1,077,898

Other Assets 596,022 604,780

Total Assets $ 5,097,783 $ 5,252,719

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY

Short-Term Obligations $ 222,166 $ 343,531

Accounts Payable, Accrued and Other Liabilities 840,867 822,913

Total Current Liabilities 1,063,033 1,166,444

Long-Term Obligations 1,143,370 1,139,433

Deferred Liabilities and Other 217,129 234,617

Total Liabilities 2,423,532 2,540,494

Redeemable Noncontrolling Interests 26,694 26,244

Total Mezzanine Equity 26,694 26,244

AptarGroup, Inc. Stockholders' Equity 2,629,495 2,668,096

Noncontrolling Interests in Subsidiaries 18,062 17,885

Total Stockholders' Equity 2,647,557 2,685,981

Total Liabilities, Mezzanine Equity and Stockholders' Equity $ 5,097,783 $ 5,252,719

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Statement of Cash Flows

Three Months Ended March 31,

2026

2025

Cash Flows from Operating Activities:

Net income $ 72,767 $ 78,663

Adjustments to reconcile net income to net cash provided by operations:

Depreciation 64,310 54,903

Amortization 11,415 10,744

Stock-based compensation 16,764 19,193

Provision for CECL 644 35

Loss (gain) on disposition of fixed assets 81 (271)

Net loss on remeasurement of equity securities 1,086 1,096

Deferred income taxes (4,567) (1,860)

Defined benefit plan expense 3,443 3,277

Equity in results of affiliates (714) (2,086)

Impairment loss 901 —

Changes in balance sheet items, excluding effects from foreign currency adjustments:

Accounts and other receivables (33,030) (69,247)

Inventories (16,943) (6,043)

Prepaid and other current assets (12,393) (12,617)

Accounts payable, accrued and other liabilities 36,422 33,324

Income taxes payable 103 (7,195)

Retirement and deferred compensation plan (15,271) (11,751)

Other changes, net (6,324) (7,423)

Net Cash Provided by Operations 118,694 82,742

Cash Flows from Investing Activities:

Capital expenditures (65,396) (56,862)

Proceeds from sale of property, plant and equipment 1,327 79

Purchases of short-term investments, net (103) (88)

Acquisition of intangible assets, net (592) (2,475)

Notes receivable, net (335) 2,714

Net Cash Used by Investing Activities (65,099) (56,632)

Cash Flows from Financing Activities:

Proceeds from notes payable and overdrafts 2,930 79

Repayments of notes payable and overdrafts (2,895) —

Proceeds and (repayments) of short term revolving credit facility, net 7,000 (23,880)

Proceeds from long-term obligations 5,037 124

Repayments of long-term obligations (127,927) (4,552)

Payment of contingent consideration obligation (2,197) —

Dividends paid (30,920) (29,923)

Proceeds from stock option exercises 18,516 3,375

Purchase of treasury stock (99,973) (80,000)

Redeemable noncontrolling interest 89 —

Net Cash Used by Financing Activities (230,340) (134,777)

Effect of Exchange Rate Changes on Cash (3,150) 10,662

Net Decrease in Cash and Equivalents and Restricted Cash (179,895) (98,005)

Cash and Equivalents and Restricted Cash at Beginning of Period 404,849 223,844

Cash and Equivalents and Restricted Cash at End of Period $ 224,954 $ 125,839

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

Three Months Ended

March 31, 2026

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 982,868 $ 438,560 $ 363,635 $ 180,673 $ — $ —

Reported net income $ 72,767

Reported income taxes 21,004

Reported income before income taxes 93,771 106,658 14,458 9,184 (23,229) (13,300)

Adjustments:

Restructuring initiatives 1,086 5 1,301 249 (469)

Net investment loss 1,086 — — — 1,086

Transaction costs related to acquisitions 45 45 — — —

Purchase accounting adjustments related to acquisitions and investments 145 145 — — —

Other special items 3,727 3,727 — — —

Adjusted earnings before income taxes 99,860 110,580 15,759 9,433 (22,612) (13,300)

Interest expense 16,942 16,942

Interest income (3,642) (3,642)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 113,160 110,580 15,759 9,433 (22,612) —

Depreciation and amortization 75,725 35,643 24,723 14,224 1,135

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 188,885 $ 146,223 $ 40,482 $ 23,657 $ (21,477) $ —

Reported net income margins (Reported net income / Reported Net Sales) 7.4 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 19.2 % 33.3 % 11.1 % 13.1 %

Three Months Ended

March 31, 2025

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 887,305 $ 409,467 $ 305,707 $ 172,131 $ — $ —

Reported net income $ 78,663

Reported income taxes 27,352

Reported income before income taxes 106,015 111,112 16,681 12,333 (25,574) (8,537)

Adjustments:

Restructuring initiatives 2,042 190 395 1,352 105

Net investment loss 1,096 — — — 1,096

Adjusted earnings before income taxes 109,153 111,302 17,076 13,685 (24,373) (8,537)

Interest expense 11,351 11,351

Interest income (2,814) (2,814)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 117,690 111,302 17,076 13,685 (24,373) —

Depreciation and amortization 65,647 31,148 20,062 13,575 862 —

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 183,337 $ 142,450 $ 37,138 $ 27,260 $ (23,511) $ —

Reported net income margins (Reported net income / Reported Net Sales) 8.9 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 20.7 % 34.8 % 12.1 % 15.8 %

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)

Three Months Ended

March 31,

2026 2025

Income before Income Taxes $ 93,771 $ 106,015

Adjustments:

Restructuring initiatives 1,086 2,042

Net investment loss 1,086 1,096

Transaction costs related to acquisitions 45 —

Purchase accounting adjustments related to acquisitions and investments 145 —

Other special items 3,727 —

Foreign currency effects (1) 8,992

Adjusted Earnings before Income Taxes $ 99,860 $ 118,145

Provision for Income Taxes $ 21,004 $ 27,352

Adjustments:

Restructuring initiatives 279 506

Net investment loss 266 269

Transaction costs related to acquisitions 11 —

Purchase accounting adjustments related to acquisitions and investments 49 —

Other special items 953 —

Foreign currency effects (1) 2,320

Adjusted Provision for Income Taxes $ 22,562 $ 30,447

Net (Income) Loss Attributable to Noncontrolling Interests $ (4) $ 135

Net Income Attributable to Redeemable Noncontrolling Interests $ (89) $ —

Net Income Attributable to AptarGroup, Inc. $ 72,674 $ 78,798

Adjustments:

Restructuring initiatives 807 1,536

Net investment loss 820 827

Transaction costs related to acquisitions 34 —

Purchase accounting adjustments related to acquisitions and investments 96 —

Other special items 2,774 —

Foreign currency effects (1) 6,672

Adjusted Net Income Attributable to AptarGroup, Inc. $ 77,205 $ 87,833

Average Number of Diluted Shares Outstanding 64,834 67,491

Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.12 $ 1.17

Adjustments:

Restructuring initiatives 0.01 0.02

Net investment loss 0.01 0.01

Transaction costs related to acquisitions — —

Purchase accounting adjustments related to acquisitions and investments — —

Other special items 0.05 —

Foreign currency effects (1) 0.10

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.19 $ 1.30

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.

AptarGroup, Inc.

Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)

(In Thousands)

Three Months Ended

March 31,

2026 2025

Net Cash Provided by Operations $ 118,694 $ 82,742

Capital Expenditures (65,396) (56,862)

Free Cash Flow $ 53,298 $ 25,880

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)

Three Months Ending

June 30,

Expected 2026

2025

Income before Income Taxes $ 139,714

Adjustments:

Restructuring initiatives 1,579

Net investment gain (2,102)

Transaction costs related to acquisitions 344

Foreign currency effects (1) 919

Adjusted Earnings before Income Taxes $ 140,454

Provision for Income Taxes $ 27,982

Adjustments:

Restructuring initiatives 421

Net investment gain (515)

Transaction costs related to acquisitions 86

Foreign currency effects (1) 184

Adjusted Provision for Income Taxes $ 28,158

Net Income Attributable to Noncontrolling Interests $ (12)

Net Income Attributable to AptarGroup, Inc. $ 111,720

Adjustments:

Restructuring initiatives 1,158

Net investment gain (1,587)

Transaction costs related to acquisitions 258

Foreign currency effects (1) 735

Adjusted Net Income Attributable to AptarGroup, Inc. $ 112,284

Average Number of Diluted Shares Outstanding 67,048

Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3) $ 1.67

Adjustments:

Restructuring initiatives 0.02

Net investment gain (0.03)

Transaction costs related to acquisitions —

Foreign currency effects (1) 0.01

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2) $1.32 - $1.40 $ 1.67

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.

(2) AptarGroup’s expected adjusted earnings per share range for the second quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 22.5% to 24.5%. This tax rate range compares to our second quarter of 2025 effective tax rate of 20.0% on both reported and adjusted earnings per share.

GRAPHIC

Filename: image.jpg · Sequence: 6

Binary file (4819 bytes)

Download image.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Apr. 30, 2026

Entity Registrant Name

AptarGroup, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-11846

Entity Tax Identification Number

36-3853103

Entity Address, Address Line One

265 Exchange Drive

Entity Address, Address Line Two

Suite 301

Entity Address, City or Town

Crystal Lake

Entity Address, State or Province

Entity Address, Postal Zip Code

60014

City Area Code

815

Local Phone Number

477-0424

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $.01 par value

Trading Symbol

ATR

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0000896622

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration